Abstract: In this large real-life single-center HCV cohort from China, oral DAAs were highly effective and well-tolerated. Further and larger-scale studies are needed to evaluate their clinical safety and efficacy.
Introduction
Direct-Acting Antivirals (DAAs) have revolutionized the treatment landscape for Chronic Hepatitis C (HCV), offering high cure rates and improved safety profiles compared to older interferon-based therapies. However, real-world data from mainland China remains limited, particularly regarding the performance of brand-name DAAs. Historically, the high cost of these medications restricted their use. In Tianjin, China, recent changes in health insurance policies—reimbursing 85–90% of treatment costs—have enabled broader access to brand-name DAAs. This study evaluates the efficacy and safety of these therapies in a real-world clinical setting.
Methods and Patient Cohort
This retrospective, single-center study was conducted at the Tianjin Second People’s Hospital, involving 494 adult patients treated between April 2018 and September 2019. The cohort included a diverse range of patient profiles, including those with cirrhosis and various HCV genotypes.
The primary endpoint was Sustained Virological Response at 12 weeks post-treatment (SVR12). Five DAA regimens were evaluated: Sofosbuvir + Ribavirin (SOF + RBV), Elbasvir/Grazoprevir (EBR/GZR), Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir ± Ribavirin (OBV/PTV/r/DSV ± RBV), Daclatasvir + Asunaprevir (DCV + ASV), and Sofosbuvir + Daclatasvir ± Ribavirin (SOF + DCV ± RBV).
Key Results
The overall SVR12 rate across the entire cohort was 96.96% (479/494). The study demonstrated that brand-name DAAs maintain high efficacy across different genotypes, treatment regimens, and patient subgroups.
Specific findings include:
- Regimen Efficacy: EBR/GZR achieved a 100% SVR12 rate, while DCV + ASV showed the lowest efficacy at 86.67%.
- Subgroup Challenges: Patients with compensated cirrhosis (92.73%) and those who were treatment-experienced (77.78%) had lower SVR12 rates compared to treatment-naive patients (97.69%).
- Genotype Sensitivity: GT3b (88.24%) and GT1a (0%, though n=1) were identified as more challenging to treat.
- Safety: No serious adverse events (SAEs) were reported. Common mild adverse events included fatigue, anemia, and dizziness, affecting 38.5% of the population.
Discussion and Conclusion
The findings confirm that brand-name DAAs are highly effective and safe for treating HCV in a real-world Chinese population, mirroring results from international clinical trials. The study highlights the importance of supportive insurance policies in achieving these outcomes. However, challenges remain for specific "difficult-to-cure" groups, such as patients with cirrhosis or prior treatment failure. Future research should focus on larger multi-center studies and the role of resistance-associated substitutions (RAS) in optimizing treatment for these subgroups.
Summary updated